SiliconANGLE Media's theCUBE Research Welcomes Security Visionaries Jackie McGuire and Jon Oltsik as Principal Analysts
PALO ALTO, Calif.--(BUSINESS WIRE)--SiliconANGLE Media, Inc. is excited to announce the addition of Jackie McGuire, a distinguished cybersecurity thought leader, economist, and data science expert to theCUBE Research team as Security Practice Lead and Principal Analyst. The company is also pleased to welcome Jon Oltsik, renowned cybersecurity analyst, as Principal Analyst in Residence.
In today's challenging security and industry research landscape, attracting proven, experienced, high-quality analysts is an ongoing challenge. McGuire and Oltsik's joining signals a significant expansion for theCUBE Research, reinforcing its commitment to growth and delivering deep analyst expertise to clients and audiences.
"Having someone on theCUBE Research team with Jackie's practical knowledge of security challenges and pragmatic understanding of practitioner realities is an incredible gift to our community," said Dave Vellante, co-founder and co-CEO of SiliconANGLE Media, Inc., and chief analyst at theCUBE Research. "Her diverse background and next-level expertise will significantly benefit our clients and audiences. As an analyst, speaker, media personality, and connector, she brings exceptional value to our network."
"We're equally thrilled to welcome Jon Oltsik to our team," Vellante added. "Jon's extensive experience and deep industry knowledge will provide unparalleled insights to our audience, particularly as he covers RSA 2025 and develops his podcast, The Cybersecurity Bridge."
Throughout her career, McGuire has been a trusted advisor to enterprises, executives, and media outlets. Her writing has been featured in leading publications such as Dark Reading, she has been a keynote and featured speaker at dozens of conferences and events, and currently hosts, co-hosts, and is a frequent guest on several podcasts. McGuire's economics background, go-to-market expertise, and ability to make cybersecurity accessible through content bring a unique advantage to both vendors and security leaders. Her research will focus on cyber security strategy, technology, policy, and bridging the talent gap in security. Her passion for enabling CISOs and security leaders to influence and achieve better outcomes through effective communication and strategy will further strengthen theCUBE Research and SiliconANGLE Media teams.
Jon Oltsik brings over 25 years of cybersecurity expertise to theCUBE. Previously a Senior Principal Analyst at Enterprise Strategy Group (ESG), Oltsik is widely recognized for pioneering research in network security, identity management, and security analytics. He has authored numerous white papers and research reports, and has regularly contributed to publications such as CSO Online, Network World, and TechTarget. His new podcast, "The Cybersecurity Bridge," explores connections between technical security challenges and business strategy, featuring conversations with industry leaders and innovators. The "bridge" metaphor represents Oltsik's goal of connecting different stakeholders in the cybersecurity community and helping them communicate more effectively, while also bridging knowledge gaps for the cybersecurity practitioner audience.
In their new roles, McGuire and Oltsik will contribute regularly to both theCUBE and SiliconANGLE platforms, which reach over 4 million readers and more than 10 million elite IT professionals, developers, SecOps professionals, technology architects, and tech-savvy business leaders. They will also support theCUBE Research's growing podcast series, focusing on the ongoing battle to secure critical infrastructure, organizational secrets, and sensitive data.
theCUBE Research combines data, primary research, analyst expertise, and media influence—powered by innovative AI and cloud technologies—to deliver high-frequency insights and exceptional client value. Its unparalleled ability to provide relevant content to specific audiences in real time, while filtering out industry noise, sets it apart. Committed to data transparency and integrity, theCUBE Research is dedicated to delivering actionable, verifiable insights for readers and clients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
28 minutes ago
- Bloomberg
Stocks Will Rally Despite Extended Dollar Declines, MLIV Pulse Survey Finds
US equities will put the worst of this year's trade-war turmoil behind them and rally to fresh highs in 2025, according to a survey of Bloomberg subscribers who attended a panel discussion on macro trends. The S&P 500 will climb to 6,500 — a better than 9% increase from Thursday's close — by year-end, according to 44% of the 27 responses in a Markets Live Pulse survey. The index was seen reaching that level by the first half of next year by 26% of participants, with 11% saying it would happen in the second half and the remainder estimating 2027 or later.
Yahoo
an hour ago
- Yahoo
JOB ALERT: Goodwill Industries of East Texas needs a WAT Trainer
Goodwill Industries of East Texas Tyler WAT Trainer Pay: $15 – $18 an hour – Full-time The incumbent in this position is primarily responsible for working with disabled individuals to provide work adjustment training services. The individual must be able to identify appropriate/ inappropriate work behavior by observing, using existing records, DARS data, and or feedback from family members; train consumer on various job duties, workplace policies and procedures/social skills/safe and efficient operation of equipment. Education/Experience: High School Diploma or GED and a Bachelor's degree in a related field, e.g., Education, Sociology, Social Services, or Liberal Arts and one year of full-time experience performing rehabilitation or adjustment; or an AA degree in a related field and 2 years of training/experience; possess computer skills (Microsoft Office Suite, Excel/Outlook). Goodwill Industries of East Texas in Tyler is looking for a WAT Trainer. Apply Here Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition filed on December 11, 2024 and communicated the Agency's intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032. About Phathom Pharmaceuticals, Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company's website at and follow on LinkedIn and StatementsThis press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about Phathom's commercialization plans. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Phathom's business, including, without limitation: the timing of the correction to the Orange Book; the expected duration of patent term extension for VOQUEZNA; we may not be able to successfully commercialize VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which will depend on a number of factors including coverage and reimbursement levels from governmental authorities and health insurers as well as market acceptance by healthcare providers; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Phathom's ability to obtain and maintain intellectual property protection, including patent term extensions, and non-patent regulatory exclusivity for vonoprazan; Phathom may face competition earlier than expected if it loses or fails to obtain any of its patent protection or non-patent regulatory exclusivity for VOQUEZNA tablets; Phathom's ability to obtain and maintain intellectual property protection and non-patent regulatory exclusivity for vonoprazan; and other risks described in the Company's prior press releases and the Company's filings with the Securities and Exchange Commission (SEC), including under the heading 'Risk Factors' in the Company's most recent Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. MEDIA CONTACTNick Benedetto1-877-742-8466media@ INVESTOR CONTACTEric Sciorilli1-877-742-8466ir@ © 2025 Phathom Pharmaceuticals. All rights VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
